are you guys planning on dumping it or waiting for the call? Currently bouncing up a bit right now but between -60 and 70%
Selling, though cutting 50% off the staff and having $ until 2026 is not terrible.
It could run if they have some ok things to say in call. Holding this 1.25 ish support so it may recover a bit but I would cut if it loses 1.25 and that 1 ish support
@here Position Closed: $ALLK
50 shares at $1.29
Profit: -$95.00
In case you want to hold longer, that’s the next catalyst for ALLK:
- AK006 (IV)
Chronic spontaneous urticaria: Phase 1 topline data expected by year end 2024.
Just want to highlight that we are still monitoring $SPRB and there is a strong anticipation of the March Catalysts.
<:pepecelebrate:899174757969317898>
<:pepecelebrate:899174757969317898>
We see a clear run up to the catalyst, up 30% from the call out, entry was not perfect. Do not wait for us to call out to take profit.
No reference to any data read outs, could push $SPRB a bit down again.
We are pleased with the play, because its a great representation of the plays we are doing since months.
@here Call out Update : $SPRB
<a:stockrocket:968516250735095828> Sold 25 Shares at 3.7 (CB: 2.8)
Hmm, I thought I had a callout in for SPRB, guess not. Anyways sold position at $3.81/share from a $2.73 average cost. Thanks guys, nice play!
<@889849212915843093> <@741367626588094495>
thoughts on LLY after NVO smashed earnings?
they have a new version of drug coming out and also they want to market to China, huge market w/ growing obesity problems
NVO guidance also said (paraphrase) that “demand is so high even if them and competitors all try their hardest they can’t meet it”
seems like a goldmine
or has LLY risen too much and is overvalued? (idk tho I bet sentiment is like “let’s get in here anyway” the idea of these companies being healthcare superpowers seems to be a good narrative, articles about them being trillion dollar companies etc. they are viewing them like healthcare Teslas)
I’m considering playing ER overnight
LLY also didn’t really ramp up after NVO did well, so that’s a plus IMO (compare to TSM rising all semis and chips, and then AMD and INTC doing poorly on ER due to being overvalued)
i would move this convo into an earnings thread for next week that someone needs to open
I am unable to start catalyst threads 
Only biotech professionals
LEERINK few months back $SPRB scenario analysis for $SPRB’s Ph.2b CAHmelia-203 data 1q24 after NBIX reports their Ph.3 results in 4Q23($NBIX a added Billions MCAP a on data CAHmelia-204 data expected in 2H24. upgrading $SPRB to Outperform (from Market Perform) raising PT to $9
1 Like
$sprb hit a 52 week high today
just stopping by to say, hot damn, SPRB just won’t stop climbing <:cheers:848949090771009536> great play